Bob Greene: Insurance industry's reason for not covering these drugs is simply cost. He says half the adult population would qualify under FDA label, if everyone used it that could potentially qualify. Greene: Industry estimates are estimating this class of drugs could eventually have sales of $150 billion a year between obesity and diabetes.